Previous Close | 1.4000 |
Open | 1.3552 |
Bid | 0.0000 x 3200 |
Ask | 0.0000 x 1000 |
Day's Range | 1.3800 - 1.4600 |
52 Week Range | 1.1050 - 3.6400 |
Volume | |
Avg. Volume | 102,736 |
Market Cap | 63.355M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.4800 |
Earnings Date | Mar 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.22 |
Q4 2022 Lucid Diagnostics Inc Earnings Call
NEW YORK, January 17, 2023--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. ("Veris"), a private digital health company focused on enhanced personalized cancer care, today provided a